Akero’s imperfect Harmony
An apparent hit in Nash has more than doubled the group’s market cap. But are the data all they seem?
Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
The Wegovy wait continues
Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.
89bio’s home run fails to excite
The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.
